What Do You Want to Know? A Reader's Survey Tells All
Learn what Applied Clinical Trial's readers told us in our annual reader's survey.
What Do You Want to Know? A Reader's Survey Tells AllDid you respond to Applied Clinical Trials' reader survey this year? Well, the results are in and those of you who did respond gave us an inside look into what clinical trials professionals are planning for their businesses in the next year and what they want to learn more about both in print and online.
New strategies that respondent's organizations would be undertaking in the next year to remain competitive included increasing efficiencies with technology (70%) and forming partnerships (58%). The hot topics that people want addressed in the next year are good clinical practice (64%), economic impact on the industry (43%), and eClinical (43%).Delving deeper into article topics, respondents want to see more on regulations, Phase II-III trials, education and training, Phase IV trials/postmarketing, and biotechnology.Check out page 8 to see the lucky respondent who won a flat screen television for participating in Applied Clinical Trials' survey this year.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.
